Uptick in Heparin-Induced Thrombocytopenia in COVID-19 Complicates Care
Two experts urge caution with the results, but suggest dialing back liberal use of therapeutic anticoagulation unless in an RCT.
Related Articles
Before a Cardiomyopathy Diagnosis, TTR Destabilization Portends Higher Mortality
The findings could potentially enable patients to be identified and treated before symptoms of ATTR-CM emerge.
Teens Who Smoke Face Risk of Cardiac Damage by Their Mid-20s
There’s no “free ticket” to keep smoking with the idea of quitting later—some changes may be irreversible, experts say.
As More Peripheral Interventions Go Radial, the AHA Offers Some Insights
The paper compares the current peripheral transradial trajectory to that of the coronary space in the mid-2000s.
ACC Offers ‘Practical Document’ for Myocarditis Diagnosis and Care
In the absence of full guidelines, this expert consensus decision pathway gives practical advice for clinicians.
TCTMD’s 2024 Cardiology Crossword Challenge
Welcome to cardiology’s jolliest—and most socially acceptable forum—for proving you paid attention to the top news of 2024! Submit your crossword answers, whether you’ve answered…
TCTMD’s 2024 Cardiology Crossword Challenge
Welcome to cardiology’s jolliest—and most socially acceptable forum—for proving you paid attention to the top news of 2024! Submit your crossword answers, whether you’ve answered…
TCTMD’s 2024 Cardiology Crossword Challenge
Welcome to cardiology’s jolliest—and most socially acceptable forum—for proving you paid attention to the top news of 2024! Submit your crossword answers, whether you’ve answered…
CVD Risks Vary by Type of Menopausal Hormone Replacement Therapy
Venous thromboembolism is a risk with several contemporary HRT formulations, consistent with earlier data.
ACURATE IDE Trial Misses Primary Endpoint in All-Risk TAVI Patients
The result calls into question the prospects of FDA approval for the Acurate neo2 valve, which is already in use globally.
Quick Takes: Hooman Allayee on the Lingering Risk of MACE for COVID-19 Patients
UK Biobank data suggest it makes sense to be vigilant about CV prevention even years after SARS-CoV-2. Hooman Allayee, PhD, explains why.